Earnings Call · Q2 FY2026·2026-08-12

Q2 26EPS +18.75%·Rev n/aQ1 26EPS 0.00%·Rev n/aQ4 25EPS +24.61%·Rev n/aQ3 25EPS +17.39%·Rev n/a⚠ consensus missing

Allogene Therapeutics, Inc. ALLO

Christine Cassiano — Chief Corporate Affairs and Brand Strategy Officer

Zachary Roberts — President and Chief Executive Officer

−4.3%1d on move date3d+0.5%5d+7.7%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ALLO calls or request research access.

More ALLO calls Browse calls Request research access